The Board of GeNeuro
Jesús Martin-Garcia
Jesús began his career in 1983 at the World Economic Foundation, and in 1989 at McKinsey & Co where he led studies in the pharmaceutical and food industries. By 1993, he chose the entrepreneurial path by creating, investing and leading start-ups in Switzerland and the United States. He was for example a co-founder of LeShop in 1996, which became the Swiss leader in e-commerce and was sold to Migros. In 2003, he created Eclosion, a public-private partnership for translating scientific discoveries in the field of life sciences into innovative drugs with disruptive potential. This unique structure was instrumental in the creation of GeNeuro, which was led by Jesús since its creation in 2006. Jesús holds a bachelor's degree in industrial sciences, a master in law from Geneva University and an MBA from Harvard Business School. He serves on the board of several biotech companies and industrial and business associations.
Michel Dubois
Michel is a Director at GeNeuro SA and President of GeNeuro Innovation SAS. He is also a Director at Stallergénes and at the Hospital St Luc St Joseph in Lyon. Michel is Honorary Consul of Canada in Lyon. He was the Director General of Institut Mérieux and a consultant at McKinsey and Arthur Andersen.
Dr. Gordon Francis
Gordon is a neurologist with outstanding expertise in the treatment of multiple sclerosis. He has played a key role in the approval of several leading MS drugs. As Vice President, Therapeutic Area Head, Neurology with Novartis, Gordon was responsible for the development and registration of Gilenya®, the world’s first oral MS treatment. Prior to Novartis, he led the team responsible for the approval and launch of Tysabri® at Elan; and earlier, he spearheaded the approval of Rebif® with Serono. Gordon previously headed the MS Clinical Research Clinic at McGill and the Clinical Research Center at the Montreal Neurological Institute. He graduated from Queen’s University medical school in Kingston, completed Internal Medicine and Neurology training at McGill University and post-doctoral Neuroimmunology training at UCSF. Gordon has published over 100 peer reviewed articles in the field of neurology.
Hedi Ben Ibrahim
Hedi Ben Brahim is the Chief Executive Officer of One Biosciences, after having been Chairman & CEO of Transgene from 2021 to 2023. He joined Transgene from Institut Mérieux where he was Vice-President for Immunotherapy. He was also the Chairman of ABL Inc., a contract research & development, and contract biomanufacturing organization (CRO/CMO). Prior to joining the Institut Mérieux, he was General Manager at a subsidiary of Vallourec, a solutions provider to the energy sector. Hedi Ben Brahim began his career in the public sector at the Ministry of the Economy, Action and Public Accounts, then at the Ministry of Social Affairs and Health. He is a graduate of the École Polytechnique and the École Nationale Supérieure des Mines de Paris.Dr. Alois B. Lang is involved in various working groups with scientific experts and regularly participates in major scientific conferences.
Giacomo di Nepi
Giacomo was Executive Vice President and Managing Director for InterMune in Europe, where he built the European organization and led the launch of Esbriet®, one of the most successful orphan drug launches in Europe. From 2006 to 2008, Giacomo was CEO of Takeda Pharmaceuticals, Europe. Between 1996 and 2006, he held various roles with Novartis, most recently as a member of the Pharma Executive Committee and Global Head of the Transplantation, Immunology and Infectious Diseases Business Unit after being CEO of Novartis Italy. Giacomo had been a Partner with McKinsey & Co. and he served as Vice President of Farmindustria, the Italian Industry Association, and as a member of the EFPIA Heads of Europe Committee. Giacomo holds a degree in Economics from Bocconi University, Milan, and an MBA from INSEAD, Fontainebleau.
Philippe Archinard
Philippe Archinard is Executive Vice President, Technological Innovation and Scientific Partnership of Institut Mérieux after having been Chairman and Chief Executive Officer of Transgene, of which he is still a director. He is also Chairman of Institut de Recherche Technologique BIOASTER and Chief Executive Officer of TSGH, a company of the Institut Mérieux Group, as well as a director of bioMérieux SA, ERYtech Pharma, NH TherAguix and ABL Inc, where he is the permanent representative of TSGH. He was previously President of bioMérieux Inc. (USA), Executive Vice President of bioMérieux SA and Chief Executive Officer of Innogenetics BV. Philippe Archinard is a graduate of the Harvard Business School.